[서울경제TV=배요한기자] On the 28th (local time), HLB’s U.S. subsidiary Elevar Therapeutics signed a license-out contract with Inceptua Group, a multinational pharmaceutical company based in Luxembourg, to sell and supply ovarian cancer treatment’Apealea’ in Europe. Revealed.
Since its establishment in Luxembourg in 1997, Inceptua is a multinational pharmaceutical company that commercializes and supplies various new drugs, including orphan drugs, through a wide network formed in Europe and Asia. It has offices in the UK, Germany, the US, China, and Japan.
In March, Eleva, which transferred Afilia’s global rights from Swedish bio company Oasmia Pharmaceutical, signed an agreement to sell Afilia in Europe, opening innovation to secure the future value of HLB Group. The (Open Innovation) strategy is paying off in earnest.
Afilia is a third-generation, improved drug of Paclitaxel, approved for use in patients who have failed the first line therapy with carboplatin for ovarian cancer, peritoneal cancer, and fallopian tube cancer, which are sensitive to platinum-based drugs. In Europe, it is the only drug for improved paclitaxel that has been approved as a treatment for ovarian cancer.
Alex Kim, CEO of Eleva, said, “We are very pleased to be able to supply Afilia to patients suffering from ovarian cancer in Europe through a partnership with Inceptua.” “Inceptua, which has a lot of experience in the development and commercialization of anticancer drugs, is “With my extensive sales network, I am the best strategic partner to maximize the value of Afilia in a short time.”
As the sales plan of Afilia in Europe became visible through the technology agreement of Eleva, the first step was put in the HLB Group’s plan to leap into a global anticancer drug company with the release of five anticancer drugs within five years. An HLB official said, “Following Vietnam’s Nanogen, which recently started clinical trials for the COVID-19 vaccine, Eleva’s ovarian cancer treatment has reached the stage of preparation for commercialization in Europe.” “Our bio ecosystem’HBS (HLB Bio eco-System)’ As each one comes to fruition, the HLB Group will transform into a global pharmaceutical group.”